rs4074785

Variant summary

Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1

The NM_058195.4(CDKN2A):​c.194-10376C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.118 in 151,486 control chromosomes in the GnomAD database, including 1,335 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.

Frequency

Genomes: 𝑓 0.12 ( 1335 hom., cov: 27)

Consequence

CDKN2A
NM_058195.4 intron

Scores

2

Clinical Significance

Not reported in ClinVar

Conservation

PhyloP100: 0.319

Publications

39 publications found
Variant links:
Genes affected
CDKN2A (HGNC:1787): (cyclin dependent kinase inhibitor 2A) This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
CDKN2A Gene-Disease associations (from GenCC):
  • melanoma, cutaneous malignant, susceptibility to, 2
    Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
  • melanoma-pancreatic cancer syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • familial atypical multiple mole melanoma syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • melanoma and neural system tumor syndrome
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -12 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.89).
BA1
GnomAd4 highest subpopulation (AMR) allele frequency at 95% confidence interval = 0.239 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CDKN2ANM_058195.4 linkc.194-10376C>T intron_variant Intron 1 of 2 ENST00000579755.2 NP_478102.2 Q8N726-1
LOC124902130XR_007061436.1 linkn.11040C>T non_coding_transcript_exon_variant Exon 2 of 2
CDKN2ANM_001363763.2 linkc.-3-10376C>T intron_variant Intron 1 of 2 NP_001350692.1
CDKN2AXM_047422597.1 linkc.-3-10376C>T intron_variant Intron 1 of 2 XP_047278553.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CDKN2AENST00000579755.2 linkc.194-10376C>T intron_variant Intron 1 of 2 1 NM_058195.4 ENSP00000462950.1 Q8N726-1

Frequencies

GnomAD3 genomes
AF:
0.118
AC:
17926
AN:
151388
Hom.:
1337
Cov.:
27
show subpopulations
Gnomad AFR
AF:
0.130
Gnomad AMI
AF:
0.0395
Gnomad AMR
AF:
0.246
Gnomad ASJ
AF:
0.0759
Gnomad EAS
AF:
0.127
Gnomad SAS
AF:
0.168
Gnomad FIN
AF:
0.100
Gnomad MID
AF:
0.0705
Gnomad NFE
AF:
0.0849
Gnomad OTH
AF:
0.114
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome
AF:
0.118
AC:
17932
AN:
151486
Hom.:
1335
Cov.:
27
AF XY:
0.122
AC XY:
9022
AN XY:
73956
show subpopulations
African (AFR)
AF:
0.130
AC:
5376
AN:
41278
American (AMR)
AF:
0.246
AC:
3738
AN:
15224
Ashkenazi Jewish (ASJ)
AF:
0.0759
AC:
263
AN:
3466
East Asian (EAS)
AF:
0.127
AC:
653
AN:
5150
South Asian (SAS)
AF:
0.168
AC:
802
AN:
4774
European-Finnish (FIN)
AF:
0.100
AC:
1040
AN:
10382
Middle Eastern (MID)
AF:
0.0694
AC:
20
AN:
288
European-Non Finnish (NFE)
AF:
0.0849
AC:
5768
AN:
67920
Other (OTH)
AF:
0.113
AC:
236
AN:
2092
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
755
1510
2264
3019
3774
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
194
388
582
776
970
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0986
Hom.:
4107
Bravo
AF:
0.132
Asia WGS
AF:
0.154
AC:
535
AN:
3478

ClinVar

Not reported in ClinVar

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.89
CADD
Benign
1.3
DANN
Benign
0.28
PhyloP100
0.32
Mutation Taster
=99/1
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs4074785; hg19: chr9-21981583; API